Download PDF
Semin Thromb Hemost 2015; 41(06): 549-555
DOI: 10.1055/s-0035-1556586
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Homeostasis of Hemostasis: The Role of Endothelium

Rashid S. Kazmi
1   Departmental of Haematology, University Hospital Southampton, Southampton, United Kingdom
,
Sara Boyce
1   Departmental of Haematology, University Hospital Southampton, Southampton, United Kingdom
,
Bashir A. Lwaleed
2   Faculty of Health Sciences, University of Southampton, Southampton, United Kingdom
› Author Affiliations
Further Information

Publication History

Publication Date:
13 August 2015 (online)

    Permissions and Reprints

Abstract

Forming an interface with virtually every other organ, endothelium has a strategic role in modulating vascular homeostasis. While its miscellany of functions includes regulation of vasomotor tone, promotion, and prevention of vascular growth, and modulation of inflammatory and hemostatic processes, it functions critically in maintaining the balance of hemostasis in health. Whereas endothelium has been recognized to influence all stages of hemostasis, new evidence suggests it to have a primary role for thrombin generation. Endothelial dysfunction is being increasingly appreciated in several pathological states and particularly, by virtue of its critical role in hemostasis, in causing thrombosis in a multitude of diseases.

Keywords

endothelium - endothelial dysfunction - homeostasis - hemostasis - thrombosis
 

  • References

  • 1 Edelberg JM, Christie PD, Rosenberg RD. Regulation of vascular bed-specific prothrombotic potential. Circ Res 2001; 89 (2) 117-124
    CrossrefPubMedGoogle Scholar
  • 2 Rosenberg RD, Aird WC. Vascular-bed—specific hemostasis and hypercoagulable states. N Engl J Med 1999; 340 (20) 1555-1564
    CrossrefPubMedGoogle Scholar
  • 3 Aird WC. Endothelial cell heterogeneity. Cold Spring Harb Perspect Med 2012; 2 (1) a006429
    PubMedGoogle Scholar
  • 4 Ishii H, Salem HH, Bell CE, Laposata EA, Majerus PW. Thrombomodulin, an endothelial anticoagulant protein, is absent from the human brain. Blood 1986; 67 (2) 362-365
    PubMedGoogle Scholar
  • 5 Levin EG, del Zoppo GJ. Localization of tissue plasminogen activator in the endothelium of a limited number of vessels. Am J Pathol 1994; 144 (5) 855-861
    PubMedGoogle Scholar
  • 6 Xu Y, Slayter HS. Immunocytochemical localization of endogenous anti-thrombin III in the vasculature of rat tissues reveals locations of anticoagulantly active heparan sulfate proteoglycans. J Histochem Cytochem 1994; 42 (10) 1365-1376
    CrossrefPubMedGoogle Scholar
  • 7 Bajaj MS, Kuppuswamy MN, Manepalli AN, Bajaj SP. Transcriptional expression of tissue factor pathway inhibitor, thrombomodulin and von Willebrand factor in normal human tissues. Thromb Haemost 1999; 82 (3) 1047-1052
    PubMedGoogle Scholar
  • 8 Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. Am J Pathol 1989; 134 (5) 1087-1097
    PubMedGoogle Scholar
  • 9 Fleck RA, Rao LV, Rapaport SI, Varki N. Localization of human tissue factor antigen by immunostaining with monospecific, polyclonal anti-human tissue factor antibody. Thromb Res 1990; 59 (2) 421-437
    CrossrefPubMedGoogle Scholar
  • 10 Ruggeri ZM, Ware J. von Willebrand factor. FASEB J 1993; 7 (2) 308-316
    PubMedGoogle Scholar
  • 11 Wagner DD. Cell biology of von Willebrand factor. Annu Rev Cell Biol 1990; 6: 217-246
    CrossrefPubMedGoogle Scholar
  • 12 Fay PJ, Coumans JV, Walker FJ. von Willebrand factor mediates protection of factor VIII from activated protein C-catalyzed inactivation. J Biol Chem 1991; 266 (4) 2172-2177
    PubMedGoogle Scholar
  • 13 Pusztaszeri MP, Seelentag W, Bosman FT. Immunohistochemical expression of endothelial markers CD31, CD34, von Willebrand factor, and Fli-1 in normal human tissues. J Histochem Cytochem 2006; 54 (4) 385-395
    CrossrefPubMedGoogle Scholar
  • 14 Nightingale TD, White IJ, Doyle EL , et al. Actomyosin II contractility expels von Willebrand factor from Weibel-Palade bodies during exocytosis. J Cell Biol 2011; 194 (4) 613-629
    CrossrefPubMedGoogle Scholar
  • 15 Valentijn KM, van Driel LF, Mourik MJ , et al. Multigranular exocytosis of Weibel-Palade bodies in vascular endothelial cells. Blood 2010; 116 (10) 1807-1816
    CrossrefPubMedGoogle Scholar
  • 16 Babich V, Meli A, Knipe L , et al. Selective release of molecules from Weibel-Palade bodies during a lingering kiss. Blood 2008; 111 (11) 5282-5290
    CrossrefPubMedGoogle Scholar
  • 17 Giblin JP, Hewlett LJ, Hannah MJ. Basal secretion of von Willebrand factor from human endothelial cells. Blood 2008; 112 (4) 957-964
    CrossrefPubMedGoogle Scholar
  • 18 Zhou C, Chen H, Lu F , et al. Cav3.1 (alpha1G) controls von Willebrand factor secretion in rat pulmonary microvascular endothelial cells. Am J Physiol Lung Cell Mol Physiol 2007; 292 (4) L833-L844
    CrossrefPubMedGoogle Scholar
  • 19 Wu S, Haynes Jr J, Taylor JT , et al. Cav3.1 (alpha1G) T-type Ca2+ channels mediate vaso-occlusion of sickled erythrocytes in lung microcirculation. Circ Res 2003; 93 (4) 346-353
    CrossrefPubMedGoogle Scholar
  • 20 van Mourik JA, Boertjes R, Huisveld IA , et al. von Willebrand factor propeptide in vascular disorders: A tool to distinguish between acute and chronic endothelial cell perturbation. Blood 1999; 94 (1) 179-185
    PubMedGoogle Scholar
  • 21 Contrino J, Hair G, Kreutzer DL, Rickles FR. In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nat Med 1996; 2 (2) 209-215
    CrossrefPubMedGoogle Scholar
  • 22 Osterud B, Flaegstad T. Increased tissue thromboplastin activity in monocytes of patients with meningococcal infection: related to an unfavourable prognosis. Thromb Haemost 1983; 49 (1) 5-7
    PubMedGoogle Scholar
  • 23 Vink H, Duling BR. Identification of distinct luminal domains for macromolecules, erythrocytes, and leukocytes within mammalian capillaries. Circ Res 1996; 79 (3) 581-589
    CrossrefPubMedGoogle Scholar
  • 24 Reitsma S, Slaaf DW, Vink H, van Zandvoort MA, oude Egbrink MG. The endothelial glycocalyx: composition, functions, and visualization. Pflugers Arch 2007; 454 (3) 345-359
    CrossrefPubMedGoogle Scholar
  • 25 Maroney SA, Mast AE. Expression of tissue factor pathway inhibitor by endothelial cells and platelets. Transfus Apher Sci 2008; 38 (1) 9-14
    CrossrefPubMedGoogle Scholar
    • 26 Sadler JE. Thrombomodulin structure and function. Thromb Haemost 1997; 78 (1) 392-395
      PubMedGoogle Scholar
    • 27 Laszik Z, Mitro A, Taylor Jr FB, Ferrell G, Esmon CT. Human protein C receptor is present primarily on endothelium of large blood vessels: implications for the control of the protein C pathway. Circulation 1997; 96 (10) 3633-3640
      CrossrefPubMedGoogle Scholar
    • 28 Wood JP, Ellery PE, Maroney SA, Mast AE. Biology of tissue factor pathway inhibitor. Blood 2014; 123 (19) 2934-2943
      CrossrefPubMedGoogle Scholar
    • 29 Maroney SA, Ellery PE, Wood JP, Ferrel JP, Martinez ND, Mast AE. Comparison of the inhibitory activities of human tissue factor pathway inhibitor (TFPI)α and TFPIβ. J Thromb Haemost 2013; 11 (5) 911-918
      CrossrefPubMedGoogle Scholar
    • 30 Esmon CT, Owen WG. Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. Proc Natl Acad Sci U S A 1981; 78 (4) 2249-2252
      CrossrefPubMedGoogle Scholar
    • 31 Esmon NL, Owen WG, Esmon CT. Isolation of a membrane-bound cofactor for thrombin-catalyzed activation of protein C. J Biol Chem 1982; 257 (2) 859-864
      PubMedGoogle Scholar
    • 32 Fukudome K, Esmon CT. Identification, cloning, and regulation of a novel endothelial cell protein C/activated protein C receptor. J Biol Chem 1994; 269 (42) 26486-26491
      PubMedGoogle Scholar
    • 33 Mohan Rao LV, Esmon CT, Pendurthi UR. Endothelial cell protein C receptor: a multiliganded and multifunctional receptor. Blood 2014; 124 (10) 1553-1562
      CrossrefPubMedGoogle Scholar
    • 34 Esmon CT. The protein C pathway. Chest 2003; 124 (3, Suppl): 26S-32S
      CrossrefPubMedGoogle Scholar
    • 35 Yanagisawa M, Kurihara H, Kimura S , et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332 (6163) 411-415
      CrossrefPubMedGoogle Scholar
    • 36 Palmer RM, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 1988; 333 (6174) 664-666
      CrossrefPubMedGoogle Scholar
    • 37 Moncada S, Gryglewski R, Bunting S, Vane JR. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976; 263 (5579) 663-665
      CrossrefPubMedGoogle Scholar
    • 38 Hanafy KA, Krumenacker JS, Murad F. NO, nitrotyrosine, and cyclic GMP in signal transduction. Med Sci Monit 2001; 7 (4) 801-819
      PubMedGoogle Scholar
    • 39 Marcus AJ, Weksler BB, Jaffe EA, Broekman MJ. Synthesis of prostacyclin from platelet-derived endoperoxides by cultured human endothelial cells. J Clin Invest 1980; 66 (5) 979-986
      CrossrefPubMedGoogle Scholar
    • 40 Mitchell JA, Ali F, Bailey L, Moreno L, Harrington LS. Role of nitric oxide and prostacyclin as vasoactive hormones released by the endothelium. Exp Physiol 2008; 93 (1) 141-147
      CrossrefPubMedGoogle Scholar
    • 41 Brunner F, Brás-Silva C, Cerdeira AS, Leite-Moreira AF. Cardiovascular endothelins: essential regulators of cardiovascular homeostasis. Pharmacol Ther 2006; 111 (2) 508-531
      CrossrefPubMedGoogle Scholar
    • 42 Böhm F, Pernow J. The importance of endothelin-1 for vascular dysfunction in cardiovascular disease. Cardiovasc Res 2007; 76 (1) 8-18
      CrossrefPubMedGoogle Scholar
    • 43 Alonso D, Radomski MW. The nitric oxide-endothelin-1 connection. Heart Fail Rev 2003; 8 (1) 107-115
      CrossrefPubMedGoogle Scholar
    • 44 Ivanciu L, Krishnaswamy S, Camire RM. New insights into the spatiotemporal localization of prothrombinase in vivo. Blood 2014; 124 (11) 1705-1714
      CrossrefPubMedGoogle Scholar
    • 45 Oliver JJ, Webb DJ, Newby DE. Stimulated tissue plasminogen activator release as a marker of endothelial function in humans. Arterioscler Thromb Vasc Biol 2005; 25 (12) 2470-2479
      CrossrefPubMedGoogle Scholar
    • 46 Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288 (5789) 373-376
      CrossrefPubMedGoogle Scholar
    • 47 Cybulsky MI, Gimbrone Jr MA. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science 1991; 251 (4995) 788-791
      CrossrefPubMedGoogle Scholar
    • 48 Hasstedt SJ, Bezemer ID, Callas PW , et al. Cell adhesion molecule 1: a novel risk factor for venous thrombosis. Blood 2009; 114 (14) 3084-3091
      CrossrefPubMedGoogle Scholar
    • 49 Tabbara IA, Ghazal CD, Ghazal HH. Early drop in protein C and antithrombin III is a predictor for the development of venoocclusive disease in patients undergoing hematopoietic stem cell transplantation. J Hematother 1996; 5 (1) 79-84
      CrossrefPubMedGoogle Scholar
    • 50 Celermajer DS, Sorensen KE, Gooch VM , et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340 (8828) 1111-1115
      CrossrefPubMedGoogle Scholar
    • 51 Salat C, Holler E, Kolb HJ , et al. Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplantation. Blood 1997; 89 (6) 2184-2188
      PubMedGoogle Scholar